Document is current

Article History

Received: 27 March 2024

Accepted: 10 June 2024

First Online: 29 July 2024

Acknowledgements

: We thank all the participants who dedicated their time and efforts to completing this study. We would like to equally acknowledge the contributions of the diabetes nurses (D. Bouchard, M. Raffray, V. Parent and M. Devaux) at Montreal Clinical Research Institute for conducting the interventions; the biostatistician C. Grou (Montreal Clinical Research Institute) for conducting the statistical analysis; and S. Haag (nurse at Montreal Clinical Research Institute) for her work on the graphical abstract.Our clinical research projects are conducted in close collaboration with patient partners of the BETTER registry (Behaviours, Therapies, Technologies, and the hypoglycaemic risk for Type 1 diabetes), co-developed with patient partners. This registry encompasses the patient-reported outcomes of over 4000 individuals living with type 1 diabetes. Subsequently, our findings are shared directly with patient partners and disseminated widely through the BETTER newsletter, website/blog, and informative webinars. Patients receive a summary of study results after publication.

: Data are available upon reasonable request.

: This study was funded by Novo Nordisk Canada.

: Novo Nordisk funded this trial through an unrestricted grant for investigator-initiated studies. RR-L: Research grants: Diabetes Canada, AstraZeneca, E Lilly, Cystic Fibrosis Canada, CIHR, FFRD, Janssen, JDRF, Merck, NIH, Novo Nordisk, Société Francophone du Diabète, Sanofi-Aventis, Vertex Pharmaceutical. Consulting/advisory panel: Abbott, AstraZeneca, Bayer, Boehringer I, Dexcom, E Lilly, HLS Therapeutics, INESSS, Insulet, Janssen, Medtronic, Merck, Novo Nordisk, Pfizer, Sanofi-Aventis. Honoraria for conferences: Abbott, AstraZeneca, Boehringer I, CPD Network, Dexcom, CMS Canadian Medical & Surgical Knowledge Translation Research Group, E Lilly, Janssen, Medtronic, Merck, Novo Nordisk, Sanofi-Aventis, Tandem, Vertex Pharmaceutical. Consumable gift (in kind): E Lilly, Medtronic. Unrestricted grants for clinical and educational activities: Abbott, E Lilly, Medtronic, Merck, Novo Nordisk, Sanofi-Aventis. Patent: T2D risk biomarkers, catheter life. Purchase fees: E Lilly (artificial pancreas). The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.

: RR-L, JM, EM-C and ST were involved in the conception, design and conduct of the study and the analysis and interpretation of the results. RS-A, CS and VB were involved in the conception of the study and data acquisition. NT and EH were involved in the analysis and interpretation of the results. JM and EM-C wrote the first draft of the manuscript, and all authors edited, reviewed and approved the final version of the manuscript. RR-L is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.